α-FORMULATION™ SCREEN

Alpha Formulation™ screens—the earliest formulation screens in the industry—rapidly identify optimal vehicles for preclinical drug dosing in mere days and often using only a single milligram of a new chemical entity (NCE).

The outcome of a screen is knowledge of the preclinical formulation options for an NCE —the Alpha Formulation™—to deliver pharmacokinetic, efficacy, and safety from first dosing to first-in-human.

Historically, formulation optimization in preclinical development has been an iterative best guess or trial-and-error process due to the high material requirements of traditional technologies. Finding the single optimal Alpha Formulation™ at the outset of preclinical development slashes timelines and de-risks the path to IND.

Alpha Formulation™ screens are only available with The Solubility Company’s proprietary SPA® platform.

Screening the solubility landscape for oral and parenteral delivery of a candidate molecule across the whole solubility landscape—aqueous buffers, biorelevant media, solvents, complexation agents, surfactants, lipids, oils, suspending agents, and crystallization inhibitors—provides a comprehensive view of a molecule.

By evaluating solubility, dissolution, and logP from just one milligram of material, researchers can comprehensively fingerprint their NCE and confidently identify the best formulation strategies to deliver efficacy and safety.

This unique, miniaturized, and data-driven approach accelerates and ensures a streamlined transition through the preclinical pipeline.